Inactive Instrument

Highlights Oxygen Biotherapeutics Inc Nasdaq

Equities

US69207P3082

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-14	Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	02-20	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	02-08	MT
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	02-07	CI
Reverse Split: 1 of 80	01-02	FA
Tenax Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure	11-13	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	23-07-19	CI
Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application	23-05-31	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
North American Morning Briefing : Meta to Buoy Nasdaq Again	23-02-02	DJ
Tenax Receives Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)	23-02-01	CI
Reverse Split: 1 of 20	23-01-04	FA
Tenax Therapeutics to Effect 1-for-20 Reverse Stock Split	23-01-04	MT
Tenax Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Tenax Therapeutics, Inc. Announces the Presentation of Positive Data from a Study of PH-HFpEF Patients Being Treated with Oral Levosimendan	22-10-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oxygen Biotherapeutics Inc Nasdaq

Equities

US69207P3082

Highlights

Filters